Eli Lilly and Company (LLY)vsStrata Critical Medical, Inc. (SRTA)
LLY
Eli Lilly and Company
$989.87
+2.37%
HEALTHCARE · Cap: $869.41B
SRTA
Strata Critical Medical, Inc.
$5.47
-3.36%
HEALTHCARE · Cap: $462.05M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 31508% more annual revenue ($72.25B vs $228.58M). LLY leads profitability with a 35.0% profit margin vs 20.6%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SRTA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+60.7%
Fair Value
$11.33
Current Price
$5.47
$5.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Keeps 21 of every $100 in revenue as profit
Reasonable price relative to book value
Revenue surging 24.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SRTA
The strongest argument for SRTA centers on Profit Margin, Price/Book, Revenue Growth. Profitability is solid with margins at 20.6% and operating margin at -2.5%. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SRTA
The primary concerns for SRTA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
SRTA carries more volatility with a beta of 2.15 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 49/100), backed by strong 35.0% margins and 55.5% revenue growth. SRTA offers better value entry with a 60.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Strata Critical Medical, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?